论文部分内容阅读
目的探讨Neu-P11对急性高眼压大鼠眼压及视网膜胶质原纤维酸性蛋白(glial fibrillary acid protein,GFAP)表达的影响。方法24只雄性SD大鼠随机分为:正常对照组、高眼压组、褪黑素治疗组和Neu-P11治疗组,每组6只,后3组采用Trendelenburg卧位法建立高眼压模型,各组通过眼角膜滴注方法给药。正常对照组和高眼压组滴注10μL生理盐水,褪黑素治疗组和Neu-P11治疗组分别滴注10μL 100μmol·L~(-1)褪黑素和NeuP11药物治疗,给药后休息2 h,再次置于卧位45 min后每小时测1次眼压,共6次,观察1周,重复实验1次。实验末注射过量戊巴比妥钠处死大鼠,留取各组大鼠眼球常规组织学切片观察SD大鼠视网膜形态学变化;免疫组织化学染色观察视网膜GFAP的表达。结果正常对照组眼压为(13.61±0.55)mmHg(1 kPa=7.5 mmHg),高眼压组眼压为(41.26±1.73)mmHg(P<0.01),即急性高眼压大鼠模型建立成功。与正常对照组相比,高眼压组大鼠视网膜水肿增厚,层次不清晰,GFAP表达呈强阳性。而褪黑素治疗组和Neu-P11治疗组大鼠眼压较高眼压组显著降低,GFAP蛋白阳性表达明显减弱。结论Neu-P11能够降低急性高眼压大鼠眼压,抑制视网膜组织胶质细胞的激活,降低GFAP表达,保护视网膜。
Objective To investigate the effect of Neu-P11 on intraocular pressure and the expression of glial fibrillary acid protein (GFAP) in rats with ocular hypertension. Methods Twenty-four male Sprague-Dawley rats were randomly divided into four groups: normal control group, ocular hypertension group, melatonin treatment group and Neu-P11 treatment group, with 6 rats in each group. Tensilepine pressure , Each group was administered by corneal instillation method. The normal control group and ocular hypertension group were instilled with 10μL normal saline, melatonin treatment group and Neu-P11 treatment group were treated with 10μL 100μmol·L -1 melatonin and NeuP11 respectively, h, once again placed in lying position 45 min after IOP every hour, a total of 6 times, observe 1 week, repeat the experiment 1 times. At the end of the experiment, rats were sacrificed by injection of sodium pentobarbital overdose. Retinal histomorphology was observed by routine histological sections of the eyeballs in each group. The expression of GFAP in retina was observed by immunohistochemical staining. Results The IOP of the control group was (13.61 ± 0.55) mmHg (1 kPa = 7.5 mmHg) and the IOP of the IOP group was (41.26 ± 1.73) mmHg (P <0.01), that is, the model of acute ocular hypertension was successfully established . Compared with the normal control group, the rats with ocular hypertension had thick retinal edema, unclear levels and strong positive GFAP expression. In the melatonin treatment group and the Neu-P11 treatment group, the intraocular pressure in the IOP group was significantly decreased, and the GFAP protein expression was significantly decreased. Conclusions Neu-P11 can reduce intraocular pressure, inhibit the activation of glial cells in retina, decrease the expression of GFAP and protect the retina in acute ocular hypertension.